1. The association between fibroblast growth factor receptor 1 gene amplification and lung cancer: a meta-analysis
- Author
-
Jian-Long Miao, Rui-Juan Liu, Jin-Hua Zhou, and Jing-Jing Cai
- Subjects
Oncology ,medicine.medical_specialty ,gene amplification ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Gene duplication ,medicine ,Systemic analysis/Meta-analysis ,030212 general & internal medicine ,Lung cancer ,Pathological ,fibroblast growth factor receptor 1 ,business.industry ,Fibroblast growth factor receptor 1 ,General Medicine ,medicine.disease ,Confidence interval ,lung cancer ,stomatognathic diseases ,Meta-analysis ,Relative risk ,Medicine ,Adenocarcinoma ,business - Abstract
Introduction Identifying target oncogenic alterations in lung cancer represents a major development in disease management. We examined the association of fibroblast growth factor receptor 1 (FGFR1) gene amplification with pathological characteristics and geographic region. Material and methods We conducted a meta-analysis of studies published between January 2010 and October 2016. Relative risks (RR) and corresponding 95% confidence intervals (CI) were calculated regarding the rate of FGFR1 amplification in different lung cancer types and geographic region. Results Twenty-three studies (5252 patients) were included. There was heterogeneity between studies. However, in subgroup analyses for squamous cell carcinoma (SCC), small cell lung cancer (SCLC), studies using the same definition of FGFR1 amplification, and those from Australia, no significant heterogeneity was detected. The prevalence of FGFR1 amplification in these studies ranged from 4.9% to 49.2% in non-small cell lung cancer (NSCLC), 5.1% to 41.5% in SCC, 0% to 14.7% in adenocarcinoma, and 0% to 7.8% in SCLC. The prevalence of FGFR1 amplification was significantly higher in SCC than in adenocarcinoma (RR = 5.2) and SCLC (RR = 4.2). The prevalence of FGFR1 amplification ranged from 5.6% to 22.2% in Europe, 4.1% to 18.2% in the United States, 7.8% to 49.2% in Asia, and 14.2% to 18.6% in Australia. The rate of FGFR1 amplification was higher in Asians than in non-Asians (RR = 1.9) in NSCLC. Conclusions These results suggest that FGFR1 amplification occurs more frequently in SCC and in Asians. FGFR1 amplification may be a potential new therapeutic target for specific patients and lung cancer subtypes.
- Published
- 2020
- Full Text
- View/download PDF